INVESTORS & MEDIA
News Release
Regeneron to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call and Webcast on November 5, 2020
Conference Call Information
To access this call, dial (888) 660-6127 (
About Regeneron
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor Relations
914.847.7786
justin.holko@regeneron.com
Corporate Communications
914.847.3422
hala.mirza@regeneron.com
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-third-quarter-2020-financial-and-operating-results-and-host-conference-call-and-webcast-on-november-5-2020-301147030.html
SOURCE